Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorQilu Hospital of Shandong University

About this trial

This is an observational study with a case control design. This study included patients with gastric cancer confirmed by pathological diagnosis of gastric tissue, and matched the control population according to age, gender, etc. In this study, researchers collected clinical information and multiple biological samples such as saliva, serum, tissue,and feces from the study subjects. We combined multi-omics approach to explore the differences between gastric cardia cancer and non-cardia gastric cancer for early screening of gastric cancer.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Study population signing informed consent form

Age: 18-75 years old

The study population must underwent endoscopic examination and was confirmed by pathological diagnosis as gastric cancer: including high-level intraepithelial neoplasia, early gastric cancer, and advanced gastric cancer.

Disqualifiers

Those who have undergone gastrointestinal surgery within the past 1 year; Patients who have undergone neoadjuvant chemotherapy and have developed tumors in the residual stomach after previous partial gastrectomy.

Those who have used proton pump inhibitors, antibiotics, probiotics, and prebiotics daily within the past month, and those who have recently received hormone therapy.

People with infectious diseases and other digestive system diseases that interfere with the experimental results, such as inflammatory bowel disease, irritable bowel syndrome, etc.

Trial population

Case: The population in the case group signed an informed consent form, aged between 18 and 75 years. All subjects underwent endoscopic examination and were confirmed by pathological diagnosis as gastric cancer, including high-grade intraepithelial neoplasia, early gastric cancer, and advanced gastric cancer. Control: The age and gender of the study subjects in the control group were matched to the study population in the case group. The pathological results of the stomach of all subjects showed no malignant changes, including normal gastric mucosa, superficial gastritis, non atrophic gastritis, and gastric polyps, etc.

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

  • Detection of biological samples based on multi-omics analysis

    Other intervention

    In this study, we combined multi-omics analysis to study the changes of various samples such as feces, serum, and saliva, and screen key differential markers.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Case1 intervention
Group B: Control1 intervention

Trial outcomes

Primary outcomes

1

Early gastric cancer detection rate

This study combines multi-omics approach to explore the differences between tumor cohorts and healthy controls, and to assist in screening for early gastric cancer.

Time frame
36 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.